Drew Provan, BSc, MBChB, MD, FRCP, FRCPath, Queen Mary University of London, London, UK, briefly discusses recent advances in the treatment and management of immune thrombocytopenia (ITP), commenting on changes being made in clinical practice and the importance of following more individualized treatment approaches. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.